Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr50.17B
• Dividend Yield: 2.5%
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): 33.9
• Beta (1Y): 1.06
• Revenue Growth: 10.46%
• EPS Growth: -35.27%
• Country: SE
• Employees: 11,827
• Sector: Industrials
• Sector Strength: 80
• Industry: Medical - Devices
• EPS (TTM): 5.43
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 896,599
• 30 Day Avg. Volume: 1,158,625
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr241.50
• Price Target Upside: 32.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

Getinge's solid financial performance, highlighted by stable profitability and strong cash flow generation, is a key strength. However, declining EBIT margins and increased leverage are concerns. Technical indicators point to a bearish trend, and the stock's high valuation might limit future gains. While the financials are fundamentally sound, the technical and valuation aspects suggest caution.

Getinge Business Overview & Revenue Model

Company Description

Getinge AB is a global medical technology company headquartered in Sweden, specializing in providing innovative solutions for healthcare and life sciences. The company operates primarily in three segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its core products and services include advanced equipment for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science research.

How the Company Makes Money

Getinge generates revenue through the sale of its medical technology products and solutions across its three primary business segments. In the Acute Care Therapies segment, the company earns income from selling advanced medical equipment and therapies used in critical care settings, such as ventilators, extracorporeal life support, and anesthesia systems. The Life Science segment contributes through the sale of sterilization, isolation, and containment solutions tailored for pharmaceutical and biomedical research industries. In the Surgical Workflows segment, Getinge makes money from providing operating room solutions, including surgical tables, lights, and integrated workflow technologies. Additionally, the company benefits from service contracts, maintenance fees, and consumable sales related to its equipment. Strategic partnerships and collaborations with healthcare providers and research institutions also play a pivotal role in expanding its market reach and enhancing its product offerings.

Getinge Financial Statement Overview

Summary

Getinge demonstrates solid revenue growth and stable profitability with a strong gross profit margin. However, declining EBIT margins and increased leverage pose potential risks. The balance sheet is stable, though with higher leverage, and cash flow generation is strong despite a decline in free cash flow.

Income Statement

Getinge demonstrates solid profitability with a strong gross profit margin of approximately 46% and a respectable net profit margin of around 4.2% for TTM. However, both EBIT and EBITDA margins have slightly contracted compared to previous years. Revenue growth is healthy, with a year-over-year increase of 2.3% in the TTM. The company exhibits moderate revenue growth and stable profitability, though declining EBIT margins may require attention.

Balance Sheet

The balance sheet reveals a stable financial structure with an equity ratio of about 50.7%, indicating a balanced asset financing strategy. However, the debt-to-equity ratio has increased to 0.38, reflecting higher leverage compared to prior years. Return on equity stands at 4.8% for the TTM, showing a reduction from previous periods, which suggests potential challenges in generating returns on equity.

Cash Flow

Cash flow analysis indicates a decline in free cash flow growth, with a negative growth rate of approximately -24% compared to the previous annual report. The operating cash flow to net income ratio is robust at 2.57, highlighting efficient cash generation relative to net income. Despite the decline in free cash flow, the company maintains a healthy cash conversion efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
34.76B	31.83B	28.29B	27.05B	29.82B
	Gross Profit
16.15B	14.49B	13.41B	13.58B	14.72B
	EBIT
2.85B	3.74B	3.63B	4.37B	4.78B
	EBITDA
5.31B	5.93B	5.73B	6.20B	6.46B
	Net Income Common Stockholders
1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.96B	2.73B	5.68B	4.08B	6.06B
	Total Assets
63.92B	53.59B	52.03B	44.55B	45.01B
	Total Debt
10.73B	8.08B	5.82B	4.31B	10.21B
	Net Debt
7.77B	5.41B	148.00M	230.00M	4.15B
	Total Liabilities
30.71B	23.18B	21.58B	19.38B	23.53B
	Stockholders Equity
33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow		Free Cash Flow
3.27B	1.60B	2.23B	5.63B	6.15B
	Operating Cash Flow
4.58B	2.96B	3.37B	6.56B	7.20B
	Investing Cash Flow
-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
	Financing Cash Flow
504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 181.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Negative. The current price of 181.65 is below the 20-day moving average (MA) of 185.02, below the 50-day MA of 200.36, and below the 200-day MA of 195.50, indicating a neutral trend. The MACD of -4.29 indicates Negative momentum. The RSI at 44.59 is Neutral, neither overbought nor oversold. The STOCH value of 39.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	74 Outperform	€1.06B	18.74	18.74%	―	10.46%	22.82%
SECT.B	66 Neutral	kr58.30B	100.92	36.63%	―	15.54%	39.12%
EKTA.B	64 Neutral	kr18.39B	18.26	9.87%	4.84%	-1.85%	-27.56%
Sector *	64 Neutral	$4.24B	11.64	5.23%	249.83%	4.07%	-10.54%
GETI.B	56 Neutral	kr50.17B	33.92	4.70%	2.50%	10.46%	-35.27%
BACTI.B	46 Neutral	€1.05B	―	-7.30%	―	23.51%	80.47%
SEDANA	46 Neutral	€1.23B	―	-5.61%	―	13.66%	-139.90%